1.
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-la...
by Marabelle, Aurélien
The lancet oncology, 2020-10, Vol.21 (10), p.1353-1365
2.
Cytokine patterns in patients with cancer: a systematic review
by Lippitz, Bodo E, Prof
The lancet oncology, 2013, Vol.14 (6), p.e218-e228
3.
An inhibitor of oxidative phosphorylation exploits cancer vulnerability
by Molina, Jennifer R
Nature medicine, 2018-07, Vol.24 (7), p.1036-1046
4.
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade
by Yuen, Kobe C
Nature medicine, 2020-05-01, Vol.26 (5), p.693-698
6.
Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation
by Thomas, Andrew Maltez
Nature medicine, 2019-04, Vol.25 (4), p.667-678
7.
Antiangiogenic therapy in oncology: current status and future directions
by Jayson, Gordon C, Prof
The Lancet (British edition), 2016, Vol.388 (10043), p.518-529
8.
Tumor-released exosomal circular RNA PDE8A promotes invasive growth via the miR-338/MACC1/MET pathway in pancreatic cancer
by Li, Zhonghu
Cancer letters, 2018-09-28, Vol.432, p.237-250
9.
Multiplexed ion beam imaging of human breast tumors
by Angelo, Michael
Nature medicine, 2014-04, Vol.20 (4), p.436-442
10.
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results fro...
by Schmid, Peter
The lancet oncology, 2020-01, Vol.21 (1), p.44-59
11.
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
by El-Khoueiry, Anthony B, Dr
The Lancet (British edition), 2017, Vol.389 (10088), p.2492-2502
12.
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, c...
by Le Tourneau, Christophe, Dr
The lancet oncology, 2015, Vol.16 (13), p.1324-1334
13.
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
by Muro, Kei, Dr
The lancet oncology, 2016, Vol.17 (6), p.717-726
14.
Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer
by Wirbel, Jakob
Nature medicine, 2019-04, Vol.25 (4), p.679-689
15.
Long non-coding RNA CASC11 interacts with hnRNP-K and activates the WNT/β-catenin pathway to promote growth and metastasis in colorectal cancer
by Zhang, Zheying
Cancer letters, 2016, Vol.376 (1), p.62-73
16.
Cancer stem cells in Osteosarcoma
by Brown, Hannah K., Dr
Cancer letters, 2016, Vol.386, p.189-195
17.
Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide
by Bengtsson, Daniel
The journal of clinical endocrinology and metabolism, 2015-04, Vol.100 (4), p.1689-1698
18.
Carcinoembryonic antigen (CEA) as tumor marker in lung cancer
by Grunnet, M
Lung cancer (Amsterdam, Netherlands), 2011, Vol.76 (2), p.138-143
19.
Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
by Denkert, Carsten, Dr
The Lancet (British edition), 2016, Vol.389 (10087), p.2430-2442
20.
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, p...
by Swain, Sandra M, Dr
The lancet oncology, 2013, Vol.14 (6), p.461-471
